J

ust two weeks after a rare rebuke from the Food and Drug Administration derailed Alkermes’s treatment for serious depression, the company has convinced the agency to change its mind and give the drug a chance.

On April 2, Alkermes said the FDA refused to even consider its approval application for a drug called ALKS-5461, citing “insufficient evidence of overall effectiveness” and sending the company’s share price down about 20 percent. On Monday, Alkermes CEO Richard Pops said the agency had reversed course, correcting a “misunderstanding” and putting ALKS-5461 on track for a yes or no decision by Jan. 31.

Unlock this article by subscribing to STAT Plus. Try it FREE for 30 days!

SUBSCRIBE TODAY

What is it?

STAT Plus is a premium subscription that delivers daily market-moving biopharma coverage and in-depth science reporting from a team with decades of industry experience.

What's included?

  • Authoritative biopharma coverage and analysis, interviews with industry pioneers, policy analysis, and first looks at cutting edge laboratories and early stage research
  • Subscriber-only networking events and panel discussions across the country
  • Monthly subscriber-only live chats with our reporters and experts in the field
  • Discounted tickets to industry events and early-bird access to industry reports

Leave a Comment

Please enter your name.
Please enter a comment.

Sign up for our Morning Rounds newsletter

Your daily dose of what’s new in health and medicine.

Privacy Policy